arrow_back Back to App

Pre-approval Drug Information Exchange: Faster Access to Therapies

This act makes it easier for pharmaceutical companies to share information about new drugs and medical devices with entities responsible for their reimbursement, even before full approval. The goal is to accelerate patient access to innovative therapies by allowing earlier planning for their availability and coverage. Citizens may gain quicker access to new treatments, but it's crucial to remember that the information shared pertains to products whose safety and effectiveness have not yet been fully established.
Key points
Pharmaceutical companies can now discuss new drugs with insurers earlier, before full approval.
This information must be truthful and include clear warnings that the product is not yet fully approved.
The aim is to bring new therapies to market faster and improve planning for patient access.
A study will be conducted after 5.5 years to assess the impact of these changes on drug access and communication.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7008
Sponsor: Rep. Guthrie, Brett [R-KY-2]
Process start date: 2022-03-09
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pre-approval Information Exchange Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7008.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-09.

What are the main provisions?

Key points include:

  • Pharmaceutical companies can now discuss new drugs with insurers earlier, before full approval.
  • This information must be truthful and include clear warnings that the product is not yet fully approved.
  • The aim is to bring new therapies to market faster and improve planning for patient access.
  • A study will be conducted after 5.5 years to assess the impact of these changes on drug access and communication.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Guthrie, Brett [R-KY-2].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health